{
    "clinical_study": {
        "@rank": "117589", 
        "arm_group": {
            "arm_group_label": "Mesenchymal progenitor cells", 
            "arm_group_type": "Experimental", 
            "description": "Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 1 x 10 E7 cells (3 ml),2 x 10 E7 cells (3 ml),5 x 10 E7 cells (3 ml). Control: PBS(Placebo) (3 ml). Frequency: 0,3 weeks. Duration:6 months."
        }, 
        "brief_summary": {
            "textblock": "Two injections in total and 3 ml autologous adipose-tissue-derived progenitor cells(haMPCs)\n      for each injection; time-points for intervention: 1) initial injection; 2) 3 weeks following\n      initial injection. The trial duration is 3 months."
        }, 
        "brief_title": "Autologous Adipose Tissue Derived Mesenchymal Progenitor Cells Therapy for Patients With Knee Osteoarthritis", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Osteoarthritis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "detailed_description": {
            "textblock": "Adipose (fat) tissue is removed by lipo-aspiration (this may take up to 40 minutes). The fat\n      is processed on-site to isolate the cells (this process takes up to 2 hours). The suspension\n      of the cells is injected into the knee joint under ultrasound guidance. (about 20 minutes)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who understand and sign the consent form for this study.\n\n          -  Age: 40-70, males and females.\n\n          -  Clinical diagnosis of degenerative arthritis by Radiographic Criteria of   Kellgren\n             and Lawrence.\n\n          -  Patients who can't treat with traditional medication and need a arthroplasty.\n\n          -  Duration of pain over Grade 4(11-point numeric scale)> 4 months.\n\n        Exclusion Criteria:\n\n          -  Women who are pregnant or breast feeding or planning to become pregnant during the\n             study.\n\n          -  Objects who administer with a anti-inflammatory drugs within 14 days prior to\n             inclusion in the study.\n\n          -  History or current evidence of alcohol or drug abuse or is a recreational user of\n             illicit drugs or prescription medications.\n\n          -  Treatment with intra-articular injection therapy within 2 months prior to screen.\n\n          -  Other joint diseases except degenerative arthritis : systemic or rheumatic or\n             inflammatory chondropathy, chondrocalcinosis, hemachromatosis, inflammatory joint\n             disease, avascular necrosis of the femoral head, Paget's disease, hemophilic\n             arthropathy, infectional arthritis, Charcot's disease, villonodular synovitis,\n             synovial chondromatosis.\n\n          -  Positive serology for HIV-1 or HIV-2, Hepatitis B (HBsAg, Anti-HCV-Ab), Hepatitis C\n             (Anti-HCV-Ab) and syphilis.\n\n          -  Serious pre-existing medical conditions like Cardiovascular Diseases, Renal Diseases,\n             Liver Diseases, Endocrine Diseases, Cancer and Diabetes Mellitus.\n\n          -  Overweight expressed as body mass index (BMI) greater than 30 (obesity grade II).\n\n          -  Participation in another clinical trial or treatment with a different investigational\n             product within 3 months prior to inclusion in the study.\n\n          -  Other pathologic conditions or circumstances that difficult participation in the\n             study according to medical criteria."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01809769", 
            "org_study_id": "CBMG-KOA-1.1"
        }, 
        "intervention": {
            "arm_group_label": "Mesenchymal progenitor cells", 
            "description": "Biological: Adipose tissue derived mesenchymal progentior cells administrated for intra-articular use", 
            "intervention_name": "Mesenchymal progenitor cells", 
            "intervention_type": "Biological", 
            "other_name": "Adipose tissue derived mesenchymal progentior cells"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200127"
                }, 
                "name": "Division of Rheumatology,Renji Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Autologous Adipose Tissue Derived Mesenchymal Progenitor Cells Therapy for Patients With Knee Osteoarthritis by Intra-articular Injection: A Phase I, Prospective, Single-Arm, Dose-escalating Clinical Trial", 
        "other_outcome": {
            "measure": "KSCRS Score(The Knee Society Clinical Rating System)", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "overall_official": {
            "affiliation": "Division of Rheumatology\uff0cRenji Hospital", 
            "last_name": "Chunde Bao, M.D. & Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "WOMAC Score(The Western Ontario and McMaster Universities Osteoarthritis Index)", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01809769"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Recording of Adverse Events and Serious Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "Cellular Biomedicine Group Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cellular Biomedicine Group Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}